Study S001610

A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin

ClinicalTrials.gov record

Registration

Registration: NCT07754461
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 600
Start: 2026-08-24
Primary completion: 2028-01-17
Lead sponsor: Boehringer Ingelheim
Conditions: Type 2 Diabetes
Interventions: DRUG:Placebo; DRUG:Survodutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41 [At baseline and Week 41.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.